Daniel Thomas

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

FDA greenlights the first precision therapy for BRCA2-mutated mCSPC, a highly aggressive prostate cancer, slashing progression risk by 54%.

AIP Realty Trust's $78.7M acquisition of AllTrades pivots on a complex related-party deal and reverse takeover, putting unitholder trust to the test.

BlackRock's latest fund distributions reveal a heavy reliance on 'return of capital,' especially in its resource funds. What does this mean for investors?

The safari park operator swung from a major loss to a $1.9M pre-tax profit, driven by revenue growth and the absence of prior-year proxy battle costs.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

Sintana Energy's all-share acquisition of Challenger gets final approval, creating a new exploration leader with high-impact assets in Namibia and Uruguay.

Rio2 diversifies from Chilean gold to Peruvian copper, securing immediate cash flow and a key position in the energy transition. What does this mean for investors?

An independent study shows Mesoblast’s cell therapy has superior remission rates over a market leader, hinting at a new standard of care and a big win for investors.

Centrus Energy is building a key Ohio facility, the first step in a multi-billion dollar plan to end US reliance on Russian uranium for next-gen reactors.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

Tevogen CEO's $100k stock gift to local police offers a case study in ESG, community engagement, and the strategic value of corporate social responsibility.

With a doubled ETH treasury and 'Synthetic Mining' yielding up to 100%, is Republic Technologies creating the blueprint for Web3 corporate finance?

S&P Global's latest report confirms Fluence's top-three status in the BESS market, driven by strategic execution and the surging demand for grid stability.

TIME's honor for AI's creators reveals a hidden truth: the digital revolution's massive energy and hardware needs are supercharging the race for minerals.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

A single crypto campaign generates $53.5B in futures volume. We dissect MEXC's strategy and what it reveals about the exchange wars and token adoption.

An upcoming memoir, "Beyond the Bronx," details one man's journey from incarceration to entrepreneurship, offering a blueprint for personal reinvention.